ProPublica published a list of investigations you may have missed due to America's governing turmoil. One is the story of Zolgensma, a gene therapy drug which gives baby's born with a rare disease a real chance to grow up and live normal lives. Despite being developed with help from taxpayers and nonprofit charities, the drug's maker debuted the drug with a $2-million per dose price tag, which set the stage for other gene therapy drugs to also have million dollar prices. ProPublica dug into the records to show how the drug was developed and why it debuted at such a high cost. "Its story upends the widely held conception that high prices reflect huge industry investments in innovation."